Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1/2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 2

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive 8Neoplasms 6Leukemia 5Neoplasms by Histologic Type 4Myeloproliferative Disorders 4Leukemia, Myeloid 4Hematologic Diseases 4Carcinoma, Non-Small-Cell Lung 4Bone Marrow Diseases 4Precursor Cell Lymphoblastic Leukemia-Lymphoma 2Lymphoproliferative Disorders 2Lymphatic Diseases 2Leukemia, Myeloid, Chronic-Phase 2Immunoproliferative Disorders 2Immune System Diseases 2Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Piebaldism 1Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL) 1Malignant Hepatobiliary Neoplasm 1Lung Neoplasms 1Leukemia, Myelomonocytic, Chronic 1Leukemia, Myeloid, Acute 1Head and Neck Neoplasms 1Glioblastoma 1Gastrointestinal Stromal Tumors 1Gastrointestinal Neoplasms 1Carcinoma, Squamous Cell 1Blast Crisis 1Adenocarcinoma of Lung 1

Interventions

blinatumomab 5Rituximab 4Cyclophosphamide 4Brentuximab Vedotin 3ponatinib 2Vincristine 2Prednisone 2Etoposide 2Doxorubicin 2tetulomab tetraxetan lu-177 1pembrolizumab 1ibrutinib 1ibritumomab tiuxetan 1fludarabine 1durvalumab 1denileukin diftitox 1cobomarsen 1Vorinostat 1Melphalan 1Lutetium 1Lenalidomide 1Imatinib Mesylate 1Ifosfamide 1Everolimus 1Cytarabine 1Carmustine 1Carboplatin 1Bendamustine Hydrochloride 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Lymphatic Diseases × ponatinib × Clear all
NCT01667133 2022-06-13

A Study of Ponatinib in Japanese Participants With Chronic Myeloid Leukemia (CML) and Ph+ Acute Lymphoblastic Leukemia (ALL)

Takeda

Phase 1/2 Completed
35 enrolled 36 charts
LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT01650805 2014-11-17

Ponatinib in Newly Diagnosed Chronic Myeloid Leukemia (CML) (EPIC)

Ariad Pharmaceuticals

Phase 3 Terminated
307 enrolled 11 charts
LymphoidMyeloidOther hematologic neoplasm

Bone Marrow Diseases, Hematologic Diseases, Immune System Diseases, Immunoproliferative Disorders, Leukemia, Leukemia, Myeloid, Lymphatic Diseases, Lymphoproliferative Disorders, Myeloproliferative Disorders, Neoplasms, Neoplasms by Histologic Type, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Data powered by HemOnc (CC BY 4.0) Colophon âš¡